Optiscan visit to US Food and Drug Administration in Washington DC for InVivage® medical device in Oral Cancer

On our late January visit to the United States, Optiscan was delighted to meet with the US Food and Drug Administration in Washington DC in relation to a 510(k) submission for the sale of the InVivage® system in human Oral Cancer in the United States. It was also a great opportunity to visit Optiscan’s partners in the Oral Cancer trial being conducted at Memorial Sloan Kettering Cancer Centre in New York and in the Anterior Cruciate Ligament (ACL) research at the University of Michigan.